
HIGH LEVEL GENTAMICIN RESISTANCE AND SUSCEPTIBILITY TO VANCOMYCIN IN ENTEROCOCCI IN A TERTIARY CARE HOSPITAL OF DHAKA CITY

Shakila Tamanna¹, Lovely Barai², AA Ahmed¹, J Ashraful Haq¹

¹Department of Microbiology, Ibrahim Medical College and ²Department of Microbiology, Bangladesh Institution of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorder (BIRDEM)

Abstract

Vancomycin and high level gentamicin resistant enterococci detection is important for effective treatment and control of nosocomial infection. The present study was undertaken to determine the species distribution of *Enterococcus* and the rate of vancomycin and high level gentamicin resistant enterococci (HLGRE) in clinical samples in a tertiary care hospital of Dhaka city. Enterococci were identified to species level by standard biochemical and serological methods. Their susceptibilities to antibiotics were determined by disc diffusion method according to CLSI guideline. Minimum inhibitory concentration (MIC) of vancomycin and gentamicin were determined by agar dilution method. The study was conducted from July 2009 to February 2010.

Among 80 isolates, 95% and 5% were identified as *Enterococcus faecalis* and *Enterococcus faecium* respectively. Out of 80 isolates 72 (90%) were sensitive and 8 (10%) were intermediate resistant to vancomycin (30µg) by disc diffusion method, but all isolates were susceptible by agar dilution MIC method. Out of 80 enterococci, 37 (46.25%) showed high level resistance to gentamicin (MIC: > 500 µg/ml) by MIC method but, initially six of which showed sensitive result to gentamicin by disc diffusion method using 120 µg disc.

The study indicated high prevalence of HLGRE in our hospital population. MIC method was more accurate in detecting high level gentamicin resistant enterococci compared to disc diffusion method with 120 µg gentamicin disc. However, none of the enterococcal strains showed resistance to vancomycin. HLGRE should be monitored regularly in clinical samples as it is difficult to treat.

Ibrahim Med. Coll. J. 2013; 7(2): 28-31

Key word: *Enterococcus*, HLGRE, VRE

Introduction

Enterococcus is a leading cause of nosocomial infections and important for its ability to acquire antibiotic resistance determinant from other organisms. *Enterococcus* includes more than 17 species. *Enterococcus faecalis* (90-95%) and *Enterococcus faecium* (5-10%) are the two species commonly present in human intestine as commensal. Other species account for less than 5% of clinical isolates. Enterococci are estimated to cause 5-15% of all cases of bacterial

endocarditis.¹ Recently, the treatment of enterococcal infections is increasingly become difficult due to emergence of antibiotic resistant strains. *E. faecium* represents most vancomycin resistant enterococci, but vancomycin resistant strains of *E. faecalis* also occur. Vancomycin resistant enterococci (VRE) are now a common cause of hospital-acquired infection and are difficult to treat pathogen with currently available antibiotics.^{2,3}

Address for Correspondence:

Prof. J. Ashraful Haq, Professor of Microbiology & Principal, Ibrahim Medical College 122 Kazi Nazrul Islam Avenue, Shahbagh, Dhaka-1000. E-mail: jhaq54@yahoo.com

Combination of a cell wall active antibiotic such as penicillin and an aminoglycoside such as gentamicin is essential for severe enterococcal infection. Although enterococci have intrinsic low-level resistance to aminoglycoside, they have synergistic susceptibility when treated with a cell wall acting antibiotic and an aminoglycoside. However, some aminoglycosides are not susceptible to synergism.^{4,5} Emergence of high level resistance to gentamicin (MIC of $> 500 \mu\text{g/ml}$) by some enterococci has caused the failure of synergistic effects of combination therapy.⁶

Along with the antibiotic pattern, rapid and accurate identification of enterococci in species level is important for appropriate drug therapy. Although studies on the rate of enterococcal infection, detection of VRE and HLGRE has been done in many countries, a few studies are done in Bangladesh. So, the present study was undertaken to determine the distribution of enterococcal species and rate of vancomycin and high level gentamicin resistant enterococci in clinical samples in a tertiary care hospital of Dhaka city.

Material and Method

Study place, samples and organisms

The study was carried out in the Department of Microbiology, Ibrahim Medical College and BIRDEM hospital, Dhaka. It was conducted from July 2009 to February 2010. All the enterococci, isolated during the period, from different clinical samples of patients attending BIRDEM hospital were included in the study for species identification and antibiotic sensitivity tests.

Microbiological methods

All samples collected during the above period were routinely cultured on blood agar media. All suspected colonies of enterococci were identified by Gram staining, cultural characteristics, motility, growth in bile esculin media and in media containing 6.5% NaCl, catalase, litmus milk reduction and L-arabinose hydrolysis tests using the standard microbiological techniques.⁷ Specific antiser (Streptex, Ramel Europe Ltd. UK) was used to determine the serogroups.

Antibiotic susceptibility testing

Antibiotic susceptibility to different antibiotics was done by Kirby-Bauer disc diffusion method and as per the recommendations of the CLSI.^{8,9} Antibiotic potency

of the disks was standardized against the reference strain *Escherichia coli* ATCC 25922 and *Staphylococcus aureus* ATCC 25923. The control organisms were included in each batch of test. All disks were obtained from Oxoid Ltd., Basingstoke, Hampshire, UK except the gentamicin 120 μg disc which was obtained from Hi-Media Laboratories Pvt. Ltd, India. Minimal inhibitory concentration (MIC) of vancomycin and gentamicin was determined by agar dilution method.¹⁰ Muller-Hinton agar plates were prepared with vancomycin concentration ranging from 0.125 $\mu\text{g/ml}$ to 128 $\mu\text{g/ml}$ and for gentamicin 0.125 $\mu\text{g/ml}$ to 4096 $\mu\text{g/ml}$. A fixed inoculum of bacteria standardized with 0.5 McFarland standards was prepared and inoculated on to the respective plates. The reading was taken after 24 hours of incubation. The highest dilution that inhibited the growth of the organism was taken as MIC of the test organism. Any *Enterococcus* showing a MIC of $> 500 \mu\text{g/ml}$ to gentamicin was considered as HLGRE. Any strain showing a MIC of $\geq 32 \mu\text{g/ml}$ to vancomycin was considered as VRE.

Results

A total of eighty enterococci were isolated during the study period. Of the 80 *Enterococcus* isolates, 71 were from urine, 8 from wounds/pus and 1 from tracheal aspirate. Among 80 isolates, 76 (95%) were *Enterococcus faecalis* and 4 (5%) were *E. faecium*. The detail antimicrobial susceptibility pattern of the 80 isolates to different antibiotics is shown in Table-1. Most of the isolates were sensitive to the tested antibiotics except ciprofloxacin and cotrimoxazole. About 82-95% enterococci was sensitive to penicillin and ampicillin. Out of 80 isolates, 72 (90%) were sensitive while 8 (10%) were intermediate resistant to vancomycin (30 μg) by disc diffusion method. But all the intermediate resistant isolates were found susceptible by agar dilution method. The MIC range of those 8 intermediate resistant enterococci was 2-4 $\mu\text{g/ml}$. Of the 80 isolates, 49 (61.25%) were sensitive while 31 (38.75%) were resistant to gentamicin by disc diffusion method. All 31 gentamicin resistant enterococci by disc diffusion method showed high level resistance (MIC $> 500 \mu\text{g/ml}$) by agar dilution method (Table-2). But, out of 49 gentamicin sensitive isolates by disc diffusion method, six isolates showed high level resistance to gentamicin. Both MIC₅₀ and MIC₉₀ of

Table-1: Antimicrobial susceptibility patterns of *Enterococcus* by disk diffusion method (n=80)

| Antimicrobial agents | Susceptibility pattern | | |
|----------------------|------------------------|------------------------|-----------|
| | Sensitive | Intermediate Resistant | Resistant |
| | n/% | n/% | n/% |
| Vancomycin (30µg) | 72/90.0 | 8/10.0* | 0 |
| Gentamicin (120µg) | 49/61.25 | 0 | 31/38.75 |
| Amikacin (30µg) | 46/57.5 | 0 | 34/42.5 |
| Netilmicin (30µg) | 58/72.5 | 0 | 22/27.5 |
| Penicillin (10µg) | 65/81.25 | 0 | 15/18.75 |
| Ampicillin (10µg) | 76/95.0 | 0 | 4/5.0 |
| Ciprofloxacin (5µg) | 23/28.75 | 0 | 57/71.25 |
| Cotrimoxazole (30µg) | 21/26.25 | 0 | 59/73.75 |

Note: *All the 8 intermediate resistant enterococci were sensitive to vancomycin by MIC method.

vancomycin were 2 µg/ml while for gentamicin it was 64 µg/ml and 4096 µg/ml respectively (Table 2).

Discussion

In our series, 88.7% enterococci were isolated from urine samples and the predominant enterococcal species identified was *E. faecalis* (95%). The reported isolation rate of *E. faecalis* from clinical samples ranged from

Table-2: Comparative susceptibility pattern of isolated enterococci to vancomycin and gentamicin by disc diffusion and agar dilution MIC method

| Antimicrobial agents | Disc Diffusion | | MIC by agar dilution | | MIC ₅₀ (µg/ml) | MIC ₉₀ (µg/ml) |
|----------------------|--------------------------------|----------------|-------------------------|----------------|---------------------------|---------------------------|
| | Zone diameter break-point (mm) | No of isolates | MIC break-point (µg/ml) | No of isolates | | |
| Vancomycin (30 µg) | S (≥17) | 72 | S (≤4) | 80 | 2 | 2 |
| | I (15-16) | 8 | I (8-16) | 0 | | |
| | R (≤14) | 0 | R (≥32) | 0 | | |
| Gentamicin (120 µg) | S(≥10) | 49 | S (≤500) | 43 | 64 | 4096 |
| | Incon(7-9) | 0 | -- | -- | | |
| | R (≤6) | 31 | R (>500) | 37 (31+6) | | |

Note: S= Susceptible I = Intermediate resistant and R= Resistant, Incon= Inconclusive. MIC of gentamicin > 2000 µg/ml was considered high level resistance.

57% to as high as 90% in different places.¹¹⁻¹⁴ This high rate of *E. faecalis* infection could be due to its virulence or its presence in the hospital environment as most of our samples were from hospitalized patients. No vancomycin resistant enterococci or VRE was detected among our eighty isolates. However, 8 (10%) isolate showed intermediate resistance to vancomycin by disc diffusion method. But all of them were found sensitive by agar dilution MIC method (MIC range 2-4 µg/ml) which indicated that disc diffusion method sometimes could be misleading in detecting vancomycin resistance. Though no VRE was detected, about 46.25% (37/80) enterococci showed high level resistance (MIC > 500 µg/ml) to gentamicin. Similar isolation rate of HLGRE has been reported by others.^{14,15} It was to be noted that about 12% (6/49) of the gentamicin sensitive isolates as detected by 120µg gentamicin disc diffusion test showed high level resistance (MIC: > 500 µg/ml) to gentamicin by MIC method. It therefore, indicated that disc diffusion test with 120µg gentamicin disc was not accurate and sensitive enough to detect HLGRE. Agar dilution MIC method was superior in identifying HLGRE.

The results of the study indicated the absence of VRE and high prevalence of HLGRE in tertiary care hospital of Dhaka city. Enterococci have both an intrinsic and acquired resistance to antibiotics, making them important nosocomial pathogens. As VRE and HLGRE are difficult to treat, resistance should be monitored regularly in a wide range of clinical samples.

References

- Brooks GF, Butel JS and Morse SA. The Streptococci. In: Jawetz, Melnick and Adelger's Medical Microbiology, 22edn. International Edition. LANGE McGraw Hill 2001; 203-216.
- Leclercq R, Derlot E, Duval J, Courvalin P. Plasmid-mediated resistance to vancomycin and teicoplanin in *E. faecium*. *N. Engl. J. Med.* 1988; **319**: 157-161.
- Fisher K and Phillips C. The ecology, epidemiology and virulence of *Enterococcus*. *Microbiology* 2009; **155**: 1749-1757
- Swenson JM, Ferraro MJ, Sahm DF, et al. Multi laboratory evaluation of screening methods for detection of high-level aminoglycoside resistance in enterococci. *Journal of Clinical Microbiology* 1995; **33**: 3008-18.
- Aslangul E, Ruimy R, Chau F, Garry L, Andremont A, Fantin B. Relationship between the level of acquired

- resistance to gentamicin and synergism with amoxicillin in *Enterococcus faecalis*. *Antimicrob. Agents Chemother* 2005; **49**(10): 4144-4148.
6. Levine DP. Vancomycin: a history. *Clinical Infectious Diseases* 2006; **42**: S5-12.
 7. Teixeira LM, Facklam RR. *Enterococcus*. In: Murray PR, Baron EJ, Jorgensne JH, Pfaller MA, Tenover FC, Tenover FC (Ed), *Manual of Clinical Microbiology*, 8th Edition, vol 1. ASM Press, Washington DC 2003; 422-433.
 8. Bauer AW, Kirby WMM, Sherris JC, and Tenover FC. Antibiotic sensitivity testing by a standardized single disk method. *American Journal of Clinical Pathology* 1966; **45**: 493-496.
 9. Performance Standards for Antimicrobial Susceptibility Testing; Seventeenth Informational Supplement. Clinical and Laboratory Standard Institute 2007; M100-S17, vol 27 (1). Wayne, Pennsylvania, USA.
 10. Washington JA, II: Susceptibility tests: agar dilution. In EH Lennette, A. Balows, W.J. Hausler and HJ Tenover (eds), *Manual of Clinical Microbiology*. 4th ed. American Society for Microbiology, Washington DC 1985; 967-971.
 11. Mutnick A, Biedenbach D, Jones RN. Geographic variations and trends in antimicrobial resistance among *Enterococcus faecalis* and *Enterococcus faecium* in the SENTRY Antimicrobial Surveillance Program (1997-2000). *Diagn Microbiol Infect Dis* 2003; **46**: 63-68.
 12. Love R M. *Enterococcus faecalis* – a mechanism for its role in endodontic failure. *Int Endod J* 2001; **34**: 399-40.
 13. Peciuliene V, Reynaud A H, Balciuniene L, Haapasalo M. Isolation of yeasts and enteric bacteria in root-filled teeth with chronic apical periodontitis. *Int Endod J* 2001; **34**: 429-434.
 14. Adhikari L. High-level aminoglycoside resistance and reduced susceptibility to vancomycin in nosocomial enterococci. *J Glob Infect Dis* 2010; **2**: 231-235.
 15. Chenoweth CE, Bradley SF, Terpenning MS, Zarins LT, Ramsey MA, Schaberg DR, Kauffman CA. Colonization and transmission of high level gentamicin-resistant enterococci in a long-term care facility. *Infection Control and Hospital Epidemiology* 1994; **15**: 703-709.